or Connect
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › INHX - Inhibitex Inc
New Posts  All Forums:Forum Nav:

INHX - Inhibitex Inc

post #1 of 99
Thread Starter 
chart.ashx?t=inhx&ta=1&p=d&s=l

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Company’s pipeline includes FV-100 for the treatment of shingles and INX-189, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C infections. The Company has additional HCV nucleotide polymerase inhibitors in preclinical development, and has also licensed the use of its proprietary MSCRAMM® protein technology to Pfizer for the development of staphylococcal vaccines.
post #2 of 99
why on earth would you wan to catch a falling knive...try IIP
post #3 of 99
Thread Starter 
Quote:
Originally Posted by tee
why on earth would you wan to catch a falling knive...try IIP
I was actually hoping to buy this dead cat before she bounced, but you have a point with the falling knife theory. That was horrible news that came out. I will buy with the first sign of forward looking news and a trend reversal. GLTA.
post #4 of 99
Thread Starter 
Quoted from 8k filed today. Looks like they are not giving up. Plus they have over $85mil in cash on hand. They have invested millions in this drug, and I don't think this is the last we will hear from them. Insiders also own a majority of the shares, they won't let this slip too far without some kind of forward looking PR. JMVHO GLTA.

“The outcome of the trial was unexpected against the background of our preclinical studies and favorable Phase II trends such that additional scrutiny is warranted,” stated William D. Johnston, Ph.D., president and chief executive officer of Inhibitex. “We plan to conduct further data analyses and laboratory studies to attempt to reconcile the Phase III data with our prior results. In addition, we will convene a panel of outside experts to review all findings related to the Veronate program. Upon the completion of these assessments, we will determine the appropriate next steps for Veronate. Further, our plans for Aurexis ® remain unchanged at this time, and we intend to initiate a multi-dose safety and pharmacokinetic study in patients with S. aureus bloodstream infections pending final discussions with the FDA.”
post #5 of 99
Thread Starter 
These are the Phase II results per the 8k filed on 3/3/2006, just a month ago . They completely conflict with the phase III results, so they are going to get some outside experts on it. They are also going to completely compare the two phases' results and look for inconsistencies. Granted if this drug has no effect as the Phase III trial indicates, this stock is doomed. If the company can show that the Phase III results were inaccurate back to 7.00 we go and beyond IMHO.

Inhibitex (MM) Inhibitex Presents Data From Aurexis Phase II Trial at ICAAC
-Represents Novel Antibody Approach for Treating Serious Staph Infections-

WASHINGTON, Dec. 16 /PRNewswire-FirstCall/ -- Inhibitex, Inc. (NASDAQ:INHX) today presented results from a Phase II clinical trial evaluating Aurexis as a first-line therapy, in combination with standard of care antibiotics, for serious, life-threatening Staphylococcus aureus ("staph") bloodstream infections at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. This study was primarily a test of safety and pharmacokinetics, but also represents an initial step in assessing the potential of Aurexis to improve cure rates over current standard of care therapy.

Dr. J. John Weems, Professor of Medicine, Department of Medicine, Medical University of South Carolina, a lead investigator in the study, presented results from the 60-patient Phase II trial. Patients with both hospital- associated and community-acquired staph bloodstream infections were included in the trial. Positive trends were observed in the composite primary endpoint of mortality, relapse rate and infection-related complications, and a number of secondary endpoints, including the progression in the severity of sepsis and days in the intensive care unit. Based on these findings, Inhibitex plans to initiate additional clinical studies in this indication in 2006.

"More than 60,000 cases of staph bloodstream infection occur annually in the United States," Dr. Weems reported to the conference attendees. "Associated mortality and relapse rates remain unacceptably high, and metastatic complications affect approximately one-third of these patients. Increasing antibiotic resistance to staph emphasizes the need for alternative approaches to current therapy."

Serious infections caused by staph represent a growing problem at hospitals, particularly as bacterial resistance to existing antibiotics increases. One-half of the patients in the Inhibitex study had infections caused by staph that were resistant to the most commonly used antibiotics. In addition to the challenges these infections pose to hospitals, staph infections that are serious and often resistant to antibiotics are now appearing in the community at an increasing rate. In fact, in the Inhibitex study, approximately 30% of the patients had infections that originated in the community, not in the hospital.

"Unfortunately, it is becoming evident that the development of new antibiotics is not improving outcomes or keeping pace with the increasing rates of antibiotic resistance among bacteria," said Dr. William Johnston, CEO of Inhibitex. "Our strategy at Inhibitex is to develop novel antibody-based drugs that augment current antibiotics, resulting in significantly improved therapeutic outcomes."

About Aurexis Phase II Trial

The Phase II trial was a randomized, placebo-controlled, double-blind study of 60 patients with documented staph bloodstream infections. Patients were randomized to one of two arms; standard of care antibiotic therapy plus placebo, or standard of care antibiotic therapy plus Aurexis (single administration at 20mg/kg). Nearly 60% of the patients already had serious complications from their staph infection at the time of diagnosis. Four patients in the group that received antibiotics alone met the primary composite endpoint, compared with two in the group that also received Aurexis. The other primary objectives of the study were pharmacokinetics (PK) and safety. The PK profile indicated that the plasma levels of Aurexis were lower in infected patients than those observed in healthy subjects in an earlier Phase I trial. Comparison of adverse events and laboratory values between the groups demonstrated that Aurexis was generally safe and well tolerated in this patient population. Among the secondary endpoints, progression in severity of sepsis was observed in four patients in the group that received antibiotics alone and none in the group that also received Aurexis. Total hospital days were similar for both groups of patients; however of those patients admitted to the ICU, the median duration of stay in the ICU was seven days for patients who received antibiotics alone compared to three days for patients who also received Aurexis. The median duration of mechanical ventilation use was eight days for those receiving Aurexis compared to four days for patients receiving antibiotics alone. The trial was not powered to show statistically significant differences in the primary endpoint between the cohorts. The study was conducted at 12 leading infectious disease hospitals within the United States.
post #6 of 99
If you like the look of this, then also take a look at COR also took a huge hit yesterday, another pharmaceutical but this time a pharmaceutical company with an FDA investigation into some of their preclinical data. Price dropped 50% and the fda investigation may only halt things temporarily.
post #7 of 99
Thread Starter 
Hey Alex thanks for droppin' in. I'll have to take a look.
post #8 of 99
in at 2.56 bounce baby bounce
post #9 of 99
this might hit $3+ today...
post #10 of 99
2.7 now
post #11 of 99
Thread Starter 
In at 2.72. Let's see.
post #12 of 99
2.74
post #13 of 99
2.75 now... and that is being taken out fast too!!
post #14 of 99
2.81...anyone else in this!! stockpicker..this is a nice one.
post #15 of 99
Thread Starter 
This is a great NASDAQ play. No MM bul$hit!
post #16 of 99
Thread Starter 
Quote:
Originally Posted by bingo
2.81...anyone else in this!! stockpicker..this is a nice one.
Thanks Bingo. Hope you make some green.
post #17 of 99
Thread Starter 
Takin' a dip.
post #18 of 99
Quote:
Originally Posted by StockPicker
Thanks Bingo. Hope you make some green.
already in the green. thanks. glty
post #19 of 99
Thread Starter 
Make sure to set about a 5% stop loss on this thing, but I think the upside potential is huge!
post #20 of 99
out at 2.74.
New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Penny Stocks
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › INHX - Inhibitex Inc